{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:46:45Z","timestamp":1781059605890,"version":"3.54.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2304803"],"award-info":[{"award-number":["2022YFC2304803"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971949, 82203300"],"award-info":[{"award-number":["81971949, 82203300"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Achieving Hepatitis B surface antigen (HBsAg) loss is a significant goal for chronic hepatitis B patients. This study aims to evaluate HBsAg loss in individuals with HIV\/HBV coinfection and explore the association of clinical variables with this outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We enrolled 138 individuals coinfected with HIV\/HBV and 480 HBV mono-infected individuals who initiated antiviral treatment. We employed Kaplan-Meier analysis to compare the rate of HBsAg loss between individuals with HIV\/HBV coinfection and those with HBV mono-infection. In the HIV\/HBV coinfected cohort, we used Cox proportional hazards models to assess the association between various factors and the incidence of HBsAg loss.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The cumulative HBsAg loss rate was higher among HBV\/HIV coinfected individuals (13 patients, 11.5% at year 3) compared to HBV mono-infected individuals (1 patient, 0.6%) after antiviral therapy. In the HIV\/HBV coinfected cohort, the multivariable analysis revealed that lower baseline HBsAg level (HR 0.53; 95% CI 0.38-0.74, p&amp;lt;0.001) and baseline CD4 T cell counts &amp;lt; 180 cells\/uL (HR 0.32; 95% CI 0.10-0.96, p=0.042) were associated with an increased indicator of HBsAg loss. Additionally, the receiver-operating characteristic curve analysis indicated an area under the curve of 0.771 for baseline HBsAg levels and 0.758 for baseline CD4 cell counts at year 1 in predicting HBsAg loss.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>After antiretroviral therapy, HIV\/HBV coinfected adults achieve higher rates of HBsAg loss. Baseline HBsAg quantitative and CD4 T cell counts are associated with HBsAg loss in individuals with HIV\/HBV coinfection after combined antiretroviral therapy and may inform treatment decisions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2025.1381826","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T06:52:09Z","timestamp":1739947929000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Baseline HBsAg quantitative and CD4 T cell counts are associated with HBsAg loss in people living with HIV\/HBV coinfection after combined antiretroviral therapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Muye","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GuiChan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchun","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3760\/cma.j.cn112138-20211006-00676","article-title":"Chinese guidelines for diagnosis and treatment of HIV\/AIDS (2018)","volume":"57","year":"2018","journal-title":"Zhonghua Nei Ke Za Zhi."},{"key":"B2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/QAI.0000000000002386","article-title":"Long-term TDF-inclusive ART and progressive rates of HBsAg loss in HIV-HBV coinfection-lessons for functional HBV cure","volume":"84","author":"Audsley","year":"2020","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41572-023-00452-3","article-title":"HIV infection","volume":"9","author":"Bekker","year":"2023","journal-title":"Nat. Rev. Dis. Primers."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/v13071341","article-title":"Functional cure of hepatitis B virus infection in individuals with HIV-coinfection: A literature review","volume":"13","author":"Boyd","year":"2021","journal-title":"Viruses"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7649","DOI":"10.1128\/JVI.00183-09","article-title":"Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection","volume":"83","author":"Chang","year":"2009","journal-title":"J. Virol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/infdis\/jiz450","article-title":"High rates of hepatitis B virus (HBV) functional cure among human immunodeficiency virus-HBV coinfected patients on antiretroviral therapy in Zambia","volume":"221","author":"Chihota","year":"2020","journal-title":"J. Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1053\/j.gastro.2010.08.045","article-title":"Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus","volume":"139","author":"de-Vries-Sluijs","year":"2010","journal-title":"Gastroenterology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J. Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S2468-1253(19)30344-9","article-title":"Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad","volume":"5","author":"Ghany","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s12072-022-10411-x","article-title":"Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort","volume":"16","author":"Hsu","year":"2022","journal-title":"Hepatol. Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1093\/infdis\/jiab241","article-title":"Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B","volume":"224","author":"Hsu","year":"2021","journal-title":"J. Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"ofac451","DOI":"10.1093\/ofid\/ofac451","article-title":"Hepatitis B-related hepatic flare during immune reconstitution syndrome after antiretroviral treatment initiation in an HBV surface antigen-positive patient with HIV: viroimmunological and histological characterization","volume":"9","author":"Iannetta","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01023","article-title":"Immunological efficacy of tenofovir disproxil fumarate-containing regimens in patients with HIV-HBV coinfection: A systematic review and meta-analysis","volume":"10","author":"Jiang","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut."},{"key":"B15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/cid\/cix747","article-title":"Higher mortality despite early antiretroviral therapy in human immunodeficiency virus and hepatitis B virus (HBV)-coinfected patients with high HBV replication","volume":"66","author":"Kouam\u00e9","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1086\/jid.2003.188.issue-12","article-title":"Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus\/HBV coinfection","volume":"188","author":"Lascar","year":"2003","journal-title":"J. Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1086\/jid.2005.191.issue-7","article-title":"Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection","volume":"191","author":"Lascar","year":"2005","journal-title":"J. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/cid\/ciz1170","article-title":"Global burden of hepatitis B infection in people living with human immunodeficiency virus: A systematic review and meta-analysis","volume":"71","author":"Leumi","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1178788","article-title":"CD4(+) T cell counts and soluble programmed death-1 at baseline correlated with hepatitis B surface antigen decline in HIV\/HBV coinfection during combined antiretroviral therapy","volume":"13","author":"Li","year":"2023","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1016\/j.cgh.2021.07.036","article-title":"Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 update","volume":"20","author":"Martin","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13268","article-title":"EACS Governing Board. Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021","volume":"23","author":"Ryom","year":"2022","journal-title":"HIV Medicine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1097\/QAD.0000000000001574","article-title":"HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment","volume":"31","author":"Singh","year":"2017","journal-title":"Aids."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1111\/liv.2018.38.issue-10","article-title":"ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B","volume":"38","author":"Wong","year":"2018","journal-title":"Liver Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: A systematic review and meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J. Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/infdis\/jiaa662","article-title":"Impact of immune reconstitution-induced hepatic flare on hepatitis B surface antigen loss in hepatitis B virus\/human immunodeficiency virus-1 coinfected patients","volume":"223","author":"Yoshikawa","year":"2021","journal-title":"J. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S2468-1253(18)30308-X","article-title":"Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses","volume":"4","author":"Zhou","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/infdis\/jis439","article-title":"Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV","volume":"206","author":"Zoutendijk","year":"2012","journal-title":"J. Infect. Dis."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1381826\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T06:52:12Z","timestamp":1739947932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1381826\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":28,"alternative-id":["10.3389\/fcimb.2025.1381826"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1381826","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"article-number":"1381826"}}